NCT03995212View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 25, 2019

Primary Completion Date

June 29, 2022

Study Completion Date

June 29, 2022

Conditions
Cholestatic Pruritus
Interventions
DRUG

CR845 1.0 mg

Oral CR845 1.0 mg administered twice daily

DRUG

Placebo

Oral Placebo administered twice daily

Trial Locations (14)

10065

Cara Therapeutics Study Site, New York

23606

Cara Therapeutics Study Site, Newport News

26506

Cara Therapeutics Study Site, Morgantown

33136

Cara Therapeutics Study Site, Miami

33322

Cara Therapeutics Study Site, Plantation

37232

Cara Therapeutics Study Site, Nashville

46202

Cara Therapeutics Study Site, Indianapolis

76012

Cara Therapeutics Study Site, Arlington

80907

Cara Therapeutics Study Site, Colorado Springs

92118

Cara Therapeutics Study Site, Coronado

92377

Cara Therapeutics Study Site, Rialto

94114

Cara Therapeutics Study Site, San Francisco

02114

Cara Therapeutics Study Site 2, Boston

02215

Cara Therapeutics Study Site, Boston

Sponsors
All Listed Sponsors
lead

Cara Therapeutics, Inc.

INDUSTRY